Neutral Tandem (Nasdaq: IQNT) reported earnings on Aug. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Neutral Tandem missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
 Neutral Tandem logged revenue of $68.3 million. The seven analysts polled by S&P Capital IQ expected to see net sales of $72.3 million on the same basis. GAAP reported sales were 4.9% higher than the prior-year quarter's $65.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.12. The seven earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.12 for Q2 were 40% lower than the prior-year quarter's $0.20 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 39.3%, 600 basis points worse than the prior-year quarter. Operating margin was 12.2%, 720 basis points worse than the prior-year quarter. Net margin was 5.4%, 540 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $72.9 million. On the bottom line, the average EPS estimate is $0.19.

Next year's average estimate for revenue is $287.2 million. The average EPS estimate is $0.78.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 888 members out of 911 rating the stock outperform, and 23 members rating it underperform. Among 214 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 210 give Neutral Tandem a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neutral Tandem is outperform, with an average price target of $15.20.